Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 13;14(10):3389.
doi: 10.3390/jcm14103389.

Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy

Khyati Bidani  1 , Angela G Marinovic  2 , Vishali Moond  3 , Prateek Harne  4 , Arkady Broder  5 , Nirav Thosani  6
Affiliations
Review

Treatment of Pancreatic Neuroendocrine Tumors: Beyond Traditional Surgery and Targeted Therapy

Khyati Bidani et al. J Clin Med. .

Abstract

Pancreatic neuroendocrine tumors (PNETs) are a rare subset of pancreatic neoplasms with diverse biological behavior and clinical presentations. Traditional treatment approaches, such as surgery and targeted therapies, have significantly improved outcomes. However, advancements in molecular biology, immunotherapy, and minimally invasive techniques have ushered in a new era of treatment possibilities. This manuscript explores the emerging modalities in PNET management, emphasizing the need for a multidisciplinary approach tailored to individual patient profiles.

Keywords: EUS-guided ablation; conversion surgery; immunotherapy advancements; microwave ablation; minimally invasive techniques; molecular; neoadjuvant and adjuvant therapy; pancreatic neuroendocrine tumors (PNETs); peptide receptor radionuclide therapy (PRRT); radiofrequency ablation; somatostatin analogs; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Sonbol M.B., Mazza G.L., Mi L., Oliver T., Starr J., Gudmundsdottir H., Cleary S.P., Hobday T., Halfdanarson T.R. Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: A SEER database analysis. Oncologist. 2022;27:573–578. doi: 10.1093/oncolo/oyac049. - DOI - PMC - PubMed
    1. Younis F., Shor D.B.A., Lubezky N., Geva R., Osher E., Shibolet O., Phillips A., Scapa E. Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: Prospective study. Eur. J. Gastroenterol. Hepatol. 2022;34:1111–1115. doi: 10.1097/MEG.0000000000002422. - DOI - PubMed
    1. Rossi S., Viera F.T., Ghittoni G., Cobianchi L., Rosa L.L., Siciliani L., Bortolotto C., Veronese L., Vercelli A., Gallotti A., et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: A pilot study of feasibility, efficacy, and safety. Pancreas. 2014;43:938–945. doi: 10.1097/MPA.0000000000000133. - DOI - PubMed
    1. Pai M., Habib N., Senturk H., Lakhtakia S., Reddy N., Cicinnati V.R., Kaba I., Beckebaum S., Drymousis P., Kahaleh M., et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J. Gastrointest. Surg. 2015;7:52. doi: 10.4240/wjgs.v7.i4.52. - DOI - PMC - PubMed
    1. de Andreis F.B., Boškoski I., Mascagni P., Schepis T., Bianchi A., Schinzari G., Annicchiarico B.E., Quero G., Tortora G., Alfieri S., et al. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: A single-center experience. Pancreatology. 2023;23:543–549. doi: 10.1016/j.pan.2023.05.004. - DOI - PubMed

LinkOut - more resources